[go: up one dir, main page]

ES2566033T3 - Parvovirus recombinante atenuado - Google Patents

Parvovirus recombinante atenuado Download PDF

Info

Publication number
ES2566033T3
ES2566033T3 ES11706253.9T ES11706253T ES2566033T3 ES 2566033 T3 ES2566033 T3 ES 2566033T3 ES 11706253 T ES11706253 T ES 11706253T ES 2566033 T3 ES2566033 T3 ES 2566033T3
Authority
ES
Spain
Prior art keywords
attenuated recombinant
recombinant parvovirus
attenuated
parvovirus
fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES11706253.9T
Other languages
English (en)
Inventor
Norman Spibey
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Intervet International BV
Original Assignee
Intervet International BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intervet International BV filed Critical Intervet International BV
Application granted granted Critical
Publication of ES2566033T3 publication Critical patent/ES2566033T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/23—Parvoviridae, e.g. feline panleukopenia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14311—Parvovirus, e.g. minute virus of mice
    • C12N2750/14334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14311—Parvovirus, e.g. minute virus of mice
    • C12N2750/14361—Methods of inactivation or attenuation
    • C12N2750/14362—Methods of inactivation or attenuation by genetic engineering

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Un parvovirus recombinante atenuado que comprende como genoma una secuencia de ADN de un parvovirus canino de tipo 2 atenuado, en el que el ADN que codifica la proteína de la cápside o un fragmento de la misma se sustituyen por un ADN que codifica una proteína de la cápside o un fragmento de la misma de un parvovirus canino de tipo 2c.

Description

imagen1
imagen2
imagen3
imagen4
imagen5

Claims (1)

  1. imagen1
ES11706253.9T 2010-03-05 2011-03-03 Parvovirus recombinante atenuado Active ES2566033T3 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US31103210P 2010-03-05 2010-03-05
EP10155646 2010-03-05
US311032P 2010-03-05
EP10155646 2010-03-05
PCT/EP2011/053164 WO2011107534A1 (en) 2010-03-05 2011-03-03 Recombinant attenuated parvovirus

Publications (1)

Publication Number Publication Date
ES2566033T3 true ES2566033T3 (es) 2016-04-08

Family

ID=42562704

Family Applications (1)

Application Number Title Priority Date Filing Date
ES11706253.9T Active ES2566033T3 (es) 2010-03-05 2011-03-03 Parvovirus recombinante atenuado

Country Status (10)

Country Link
US (1) US9234182B2 (es)
EP (1) EP2542260B1 (es)
JP (3) JP6200155B2 (es)
CN (1) CN102791288B (es)
AU (1) AU2011222910B2 (es)
CA (1) CA2790653C (es)
DK (1) DK2542260T3 (es)
ES (1) ES2566033T3 (es)
RU (1) RU2527157C2 (es)
WO (1) WO2011107534A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102791288B (zh) * 2010-03-05 2015-02-18 英特维特国际股份有限公司 重组的减毒细小病毒
US9314519B2 (en) 2012-08-21 2016-04-19 Intervet Inc. Liquid stable virus vaccines
US20140234354A1 (en) * 2013-02-15 2014-08-21 Boehringer Ingelheim Vetmedica, Inc. Porcine parvovirus 5b, methods of use and vaccine
AR097762A1 (es) 2013-09-27 2016-04-13 Intervet Int Bv Formulaciones secas de vacunas que son estables a temperatura ambiente
CN105263953B (zh) * 2014-01-15 2020-01-07 勃林格殷格翰动物保健美国有限公司 猪细小病毒5a、使用方法及疫苗
ES2771850T3 (es) 2014-04-17 2020-07-07 Intervet Int Bv Parvovirus porcino
FI3534939T3 (fi) 2016-11-03 2023-05-15 Boehringer Ingelheim Vetmedica Gmbh Rokote sian parvovirusta ja sian hedelmättömyyttä ja respiratorista oireyhtymää aiheuttamaa virusta vastaan ja menetelmän sen valmistamiseksi
UA127859C2 (uk) 2016-11-03 2024-01-31 Бьорінгер Інгельхайм Ветмедіка Гмбх Вакцина проти свинячого парвовірусу
MX2023005182A (es) 2020-11-04 2023-05-15 Intervet Int Bv Parvovirus canino.
CN114957406B (zh) * 2022-05-26 2024-02-02 吉林大学 一种犬细小病毒的三价抗原和三价病毒样颗粒以及应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8502399D0 (en) * 1985-01-31 1985-03-06 Akzo Nv Canine parvovirus vaccines
DE69941905D1 (de) * 1998-11-10 2010-02-25 Univ North Carolina Virusvektoren und verfahren für ihre herstellung und verabreichung.
KR20080025197A (ko) * 2005-07-28 2008-03-19 화이자 프로덕츠 인코포레이티드 백신 투여 방법, 새로운 고양이 칼리시바이러스, 및 고양이파보바이러스 및 고양이 헤르페스 바이러스에 대한 동물을면역화시키기 위한 처리
NZ599585A (en) * 2007-06-14 2013-12-20 Univ Oklahoma State Vaccines containing canine parvovirus genetic variants
CN102791288B (zh) * 2010-03-05 2015-02-18 英特维特国际股份有限公司 重组的减毒细小病毒

Also Published As

Publication number Publication date
JP2018134088A (ja) 2018-08-30
CA2790653A1 (en) 2011-09-09
JP6346143B2 (ja) 2018-06-20
US20120328652A1 (en) 2012-12-27
DK2542260T3 (en) 2016-06-06
AU2011222910B2 (en) 2014-09-18
EP2542260A1 (en) 2013-01-09
AU2011222910A1 (en) 2012-09-27
CN102791288B (zh) 2015-02-18
JP2013520977A (ja) 2013-06-10
WO2011107534A1 (en) 2011-09-09
CA2790653C (en) 2019-02-19
RU2527157C2 (ru) 2014-08-27
JP6200155B2 (ja) 2017-09-20
EP2542260B1 (en) 2016-03-02
RU2012142309A (ru) 2014-04-10
JP2016047053A (ja) 2016-04-07
BR112012021650A2 (pt) 2017-02-21
CN102791288A (zh) 2012-11-21
US9234182B2 (en) 2016-01-12

Similar Documents

Publication Publication Date Title
ES2566033T3 (es) Parvovirus recombinante atenuado
ES2569365T3 (es) Inhibición de miostatina para la potenciación de músculo y/o la mejora de la función muscular
CL2009000190A1 (es) Virus recombinante de la enfermedad de newcastle que comprende un transgen que codifica una citoquina de ave; nucleocapside y genoma de dicho virus; molecula de adn que codifica el genoma y/o antigenoma del virus; celula y composicion que lo comprenden.
ES2683695T3 (es) Repeticiones terminales invertidas restrictivas para vectores virales
CL2012001068A1 (es) Polinucleotido que codifica oleosina modificada incluyendo al menos una cisteina introducida artificialmente, constructo genetico que comprende dicho polinucleotido; célula huesped; composicion que comprende un cuerpo oleoso; alimento animal que comprende el cuerpo oleoso.
CL2012002969A1 (es) Vector viral adenoasociado recombinante (raav) que comprende promotor de rodopsina quinasa humana especifica del fotorreceptor, o promotor de beta-actina de pollo cmv quimerico truncado ubicuo unido a al menos un adn que codifica una guanilato ciclasa; virion o particula viral infecciosa que comprende el vector; celula huesped; composicion que comprende el vector.
MX2018007237A (es) Proteinas de cápside modificadas para un suministro mejorado de vectores de parvovirus.
AR079881A1 (es) Plantas tolerantes a herbicidas inhibidores de las hppd
EP3795581A3 (en) New avv capsid proteins for nucleic acid transfer
AR079883A1 (es) Plantas tolerantes a herbicidas inhibidores de las hppd
AR079972A1 (es) Plantas tolerantes a herbicidas inhibidores de las hppd
EA201270423A1 (ru) Ингибиторы протеазы hcv
JP2013510581A5 (es)
MX2016010649A (es) Vector de virus adeno-asociado.
MX384795B (es) Vectores que comprenden secuencias de polinucleotidos rellenadoras/de relleno y metodos de uso.
CO6400192A2 (es) Inhibidores del virus de la hepatitis c
EA201001045A1 (ru) Модифицированный вирус гриппа
BR112012003837B8 (pt) Vacina de paramyxovírus aviária recombinante e método para fazer e usar a mesma
MY173789A (en) North american porcine reproductive and respiratory syndrome (prrs) virus and uses thereof
CL2011002941A1 (es) Sales de disacarina, acido difumarico, acido di-1-hidroxi-2-naftoico y acido monobenzoico de 2-(4-((2-amino-4-metil-6-(pentilamino)pirimidin-5-il)metil)fenil)acetato de 4-(dimetilamino)butilo; composicion farmaceutica; y uso en el tratamiento de asma, epoc, cancer, vih, hepatitis b y c, infecciones bacterianas.
CL2014003464A1 (es) Método para mejorar la integridad deteriorada de la unión neuromuscular que comprende la administración de una composición que comprende un vector viral adeno-asociado recombinante (raav) que comprende una molécula de ácido nucleico que codifica la alfa-glucosidasa ácida (gaa).
PH12014502534A1 (en) Effective vaccination against porcine reproductive and respiratory syndrome (prrs) virus prior to weaning
NL301108I2 (nl) levend recombinant canine parvovirus stam 630a
BRPI0919696A2 (pt) Polipeptídeo substancialmente purificado, microorganismo recombinante, e, polinucleotídeo isolado.
MX387400B (es) Células de mamífero que expresan antígenos de citomegalovirus.